Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. more
Time Frame | GLMD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.66% | -0.33% | -1.49% |
1-Month Return | 5.57% | -4.57% | -0.37% |
3-Month Return | -62.36% | -9.96% | 3.89% |
6-Month Return | -18.68% | -5.67% | 9.34% |
1-Year Return | -41.28% | 2.53% | 25.19% |
3-Year Return | -99.12% | -1.43% | 24.7% |
5-Year Return | -99.71% | 34.73% | 85.39% |
10-Year Return | -99.72% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 35.00K | 39.00K | 42.00K | 35.00K | 31.00K | [{"date":"2019-12-31","value":83.33,"profit":true},{"date":"2020-12-31","value":92.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.33,"profit":true},{"date":"2023-12-31","value":73.81,"profit":true}] |
Gross Profit | (35.00K) | (39.00K) | (42.00K) | (35.00K) | (31.00K) | [{"date":"2019-12-31","value":-3500000,"profit":false},{"date":"2020-12-31","value":-3900000,"profit":false},{"date":"2021-12-31","value":-4200000,"profit":false},{"date":"2022-12-31","value":-3500000,"profit":false},{"date":"2023-12-31","value":-3100000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 22.38M | 30.21M | 32.88M | 17.65M | (7.49M) | [{"date":"2019-12-31","value":68.05,"profit":true},{"date":"2020-12-31","value":91.88,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.68,"profit":true},{"date":"2023-12-31","value":-22.79,"profit":false}] |
Operating Income | (22.38M) | (30.21M) | (32.88M) | (17.65M) | 7.49M | [{"date":"2019-12-31","value":-298.67,"profit":false},{"date":"2020-12-31","value":-403.23,"profit":false},{"date":"2021-12-31","value":-438.88,"profit":false},{"date":"2022-12-31","value":-235.6,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 3.83M | 2.60M | 933.00K | 60.00K | (13.66M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.8,"profit":true},{"date":"2021-12-31","value":24.33,"profit":true},{"date":"2022-12-31","value":1.56,"profit":true},{"date":"2023-12-31","value":-356.17,"profit":false}] |
Pre-Tax Income | (20.46M) | (28.77M) | (32.47M) | (17.87M) | (6.91M) | [{"date":"2019-12-31","value":-2046100000,"profit":false},{"date":"2020-12-31","value":-2877100000,"profit":false},{"date":"2021-12-31","value":-3246700000,"profit":false},{"date":"2022-12-31","value":-1786600000,"profit":false},{"date":"2023-12-31","value":-691200000,"profit":false}] |
Income Taxes | (1.92M) | (1.16M) | (519.00K) | 705.00K | (14.98M) | [{"date":"2019-12-31","value":-272.34,"profit":false},{"date":"2020-12-31","value":-164.68,"profit":false},{"date":"2021-12-31","value":-73.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-2125.39,"profit":false}] |
Income After Taxes | (18.54M) | (27.61M) | (31.95M) | (18.57M) | 8.07M | [{"date":"2019-12-31","value":-229.7,"profit":false},{"date":"2020-12-31","value":-342.05,"profit":false},{"date":"2021-12-31","value":-395.79,"profit":false},{"date":"2022-12-31","value":-230.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (20.46M) | (28.77M) | (32.47M) | (17.87M) | (7.54M) | [{"date":"2019-12-31","value":-2046100000,"profit":false},{"date":"2020-12-31","value":-2877100000,"profit":false},{"date":"2021-12-31","value":-3246700000,"profit":false},{"date":"2022-12-31","value":-1786600000,"profit":false},{"date":"2023-12-31","value":-753500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (18.54M) | (27.61M) | (31.95M) | (18.57M) | (6.91M) | [{"date":"2019-12-31","value":-1854100000,"profit":false},{"date":"2020-12-31","value":-2761000000,"profit":false},{"date":"2021-12-31","value":-3194800000,"profit":false},{"date":"2022-12-31","value":-1857100000,"profit":false},{"date":"2023-12-31","value":-691200000,"profit":false}] |
EPS (Diluted) | (0.97) | (1.35) | (1.32) | (0.76) | (3.26) | [{"date":"2019-12-31","value":-97,"profit":false},{"date":"2020-12-31","value":-135,"profit":false},{"date":"2021-12-31","value":-132,"profit":false},{"date":"2022-12-31","value":-76,"profit":false},{"date":"2023-12-31","value":-326,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GLMD | |
---|---|
Cash Ratio | 6.82 |
Current Ratio | 7.03 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GLMD | |
---|---|
ROA (LTM) | -29.31% |
ROE (LTM) | -52.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GLMD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.12 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GLMD | |
---|---|
Trailing PE | 0.04 |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.27 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.32 |
PEG | NM |
Galmed Pharmaceuticals Ltd (GLMD) share price today is $3.04
Yes, Indians can buy shares of Galmed Pharmaceuticals Ltd (GLMD) on Vested. To buy Galmed Pharmaceuticals Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GLMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Galmed Pharmaceuticals Ltd (GLMD) via the Vested app. You can start investing in Galmed Pharmaceuticals Ltd (GLMD) with a minimum investment of $1.
You can invest in shares of Galmed Pharmaceuticals Ltd (GLMD) via Vested in three simple steps:
The 52-week high price of Galmed Pharmaceuticals Ltd (GLMD) is $15.1. The 52-week low price of Galmed Pharmaceuticals Ltd (GLMD) is $2.56.
The price-to-earnings (P/E) ratio of Galmed Pharmaceuticals Ltd (GLMD) is 0.0435
The price-to-book (P/B) ratio of Galmed Pharmaceuticals Ltd (GLMD) is 0.27
The dividend yield of Galmed Pharmaceuticals Ltd (GLMD) is 0.00%
The market capitalization of Galmed Pharmaceuticals Ltd (GLMD) is $5.02M
The stock symbol (or ticker) of Galmed Pharmaceuticals Ltd is GLMD